1
|
Foglietta F, Canaparo R, Cossari S, Panzanelli P, Dosio F, Serpe L. Ultrasound Triggers Hypericin Activation Leading to Multifaceted Anticancer Activity. Pharmaceutics 2022; 14:1102. [PMID: 35631688 PMCID: PMC9146189 DOI: 10.3390/pharmaceutics14051102] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2022] [Revised: 05/18/2022] [Accepted: 05/19/2022] [Indexed: 12/04/2022] Open
Abstract
The use of ultrasound (US) in combination with a responsive chemical agent (sonosensitizer) can selectively trigger the agent's anticancer activity in a process called sonodynamic therapy (SDT). SDT shares some properties with photodynamic therapy (PDT), which has been clinically approved, but sets itself apart because of its use of US rather than light to achieve better tissue penetration. SDT provides anticancer effects mainly via the sonosensitizer-mediated generation of reactive oxygen species (ROS), although the precise nature of the underpinning mechanism is still under debate. This work investigates the SDT anticancer activity of hypericin (Hyp) in vitro in two- (2D) and three-dimensional (3D) HT-29 colon cancer models, and uses PDT as a yardstick due to its well-known Hyp phototoxicity. The cancer cell uptake and cellular localization of Hyp were investigated first to determine the proper noncytotoxic concentration and incubation time of Hyp for SDT. Furthermore, ROS production, cell proliferation, and cell death were evaluated after Hyp was exposed to US. Since cancer relapse and transporter-mediated multidrug resistance (MDR) are important causes of cancer treatment failure, the US-mediated ability of Hyp to elicit immunogenic cell death (ICD) and overcome MDR was also investigated. SDT showed strong ROS-mediated anticancer activity 48 h after treatment in both the HT-29 models. Specific damage-associated molecular patterns that are consistent with ICD, such as calreticulin (CRT) exposure and high-mobility group box 1 protein (HMGB1) release, were observed after SDT with Hyp. Moreover, the expression of the ABC transporter, P-glycoprotein (P-gp), in HT-29/MDR cells was not able to hinder cancer cell responsiveness to SDT with Hyp. This work reveals, for the first time, the US responsiveness of Hyp with significant anticancer activity being displayed, making it a full-fledged sonosensitizer for the SDT of cancer.
Collapse
Affiliation(s)
- Federica Foglietta
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (F.F.); (R.C.); (S.C.); (L.S.)
| | - Roberto Canaparo
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (F.F.); (R.C.); (S.C.); (L.S.)
| | - Simone Cossari
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (F.F.); (R.C.); (S.C.); (L.S.)
| | - Patrizia Panzanelli
- Department of Neuroscience Rita Levi Montalcini, University of Torino, 10125 Torino, Italy;
| | - Franco Dosio
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (F.F.); (R.C.); (S.C.); (L.S.)
| | - Loredana Serpe
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (F.F.); (R.C.); (S.C.); (L.S.)
| |
Collapse
|
2
|
Argenziano M, Arpicco S, Brusa P, Cavalli R, Chirio D, Dosio F, Gallarate M, Peira E, Stella B, Ugazio E. Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research. Pharmaceutics 2021; 13:pharmaceutics13101538. [PMID: 34683830 PMCID: PMC8540327 DOI: 10.3390/pharmaceutics13101538] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 09/09/2021] [Accepted: 09/13/2021] [Indexed: 01/02/2023] Open
Abstract
Active targeting is a valuable and promising approach with which to enhance the therapeutic efficacy of nanodelivery systems, and the development of tumor-targeted nanoparticles has therefore attracted much research attention. In this field, the research carried out in Italian Pharmaceutical Technology academic groups has been focused on the development of actively targeted nanosystems using a multidisciplinary approach. To highlight these efforts, this review reports a thorough description of the last 10 years of Italian research results on the development of actively targeted nanoparticles to direct drugs towards different receptors that are overexpressed on cancer cells or in the tumor microenvironment. In particular, the review discusses polymeric nanocarriers, liposomes, lipoplexes, niosomes, solid lipid nanoparticles, squalene nanoassemblies and nanobubbles. For each nanocarrier, the main ligands, conjugation strategies and target receptors are described. The literature indicates that polymeric nanoparticles and liposomes stand out as key tools for improving specific drug delivery to the site of action. In addition, solid lipid nanoparticles, squalene nanoparticles and nanobubbles have also been successfully proposed. Taken together, these strategies all offer many platforms for the design of nanocarriers that are suitable for future clinical translation.
Collapse
Affiliation(s)
| | - Silvia Arpicco
- Correspondence: (S.A.); (M.G.); Tel.: +39-011-670-6668 (S.A.); +39-011-670-7194 (M.G.)
| | | | | | | | | | - Marina Gallarate
- Correspondence: (S.A.); (M.G.); Tel.: +39-011-670-6668 (S.A.); +39-011-670-7194 (M.G.)
| | | | | | | |
Collapse
|
3
|
Rammal H, Al Assaad A, Dosio F, Stella B, Maksimenko A, Mura S, Van Gulick L, Callewaert M, Desmaële D, Couvreur P, Morjani H, Beljebbar A. Investigation of squalene-doxorubicin distribution and interactions within single cancer cell using Raman microspectroscopy. Nanomedicine 2021; 35:102404. [PMID: 33932593 DOI: 10.1016/j.nano.2021.102404] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 03/10/2021] [Accepted: 04/08/2021] [Indexed: 11/17/2022]
Abstract
Intracellular distribution of doxorubicin (DOX) and its squalenoylated (SQ-DOX) nanoparticles (NPs) form in murine lung carcinoma M109 and human breast carcinoma MDA-MB-231 cells was investigated by Raman microspectroscopy. Pharmacological data showed that DOX induced higher cytotoxic effect than SQ-DOX NPs. Raman data were obtained using single-point measurements and imaging on the whole cell areas. These data showed that after DOX treatment at 1 μM, the spectral features of DOX were not detected in the M109 cell cytoplasm and nucleus. However, the intracellular distribution of SQ-DOX NPs was higher than DOX in the same conditions. In addition, SQ-DOX NPs were localized into both cell cytoplasm and nucleus. After 5 μM treatment, Raman bands of DOX at 1211 and 1241 cm-1 were detected in the nucleus. Moreover, the intensity ratio of these bands decreased, indicating DOX intercalation into DNA. However, after treatment with SQ-DOX NPs, the intensity of these Raman bands increased. Interestingly, with SQ-DOX NPs, the intensity of 1210/1241 cm-1 ratio was higher suggesting a lower fraction of intercalated DOX in DNA and higher amount of non-hydrolyzed SQ-DOX. Raman imaging data confirm this subcellular localization of these drugs in both M109 and MDA-MB-231 cells. These finding brings new insights to the cellular characterization of anticancer drugs at the molecular level, particularly in the field of nanomedicine.
Collapse
Affiliation(s)
- Hassan Rammal
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Almar Al Assaad
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Franco Dosio
- Department of Drug Science and Technology, University of Torino, Torino, Italy.
| | - Barbara Stella
- Department of Drug Science and Technology, University of Torino, Torino, Italy.
| | - Andrei Maksimenko
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Simona Mura
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Laurence Van Gulick
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France; Institut de Chimie Moléculaire de Reims, ICMR - UMR 7312, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Maïté Callewaert
- Institut de Chimie Moléculaire de Reims, ICMR - UMR 7312, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Didier Desmaële
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Patrick Couvreur
- Institut Galien Paris-Saclay CNRS UMR8612, Université Paris-Saclay, Faculté de Pharmacie, Châtenay-Malabry, France..
| | - Hamid Morjani
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| | - Abdelilah Beljebbar
- Translational BioSpectrocopy, BioSpecT, EA 7506, Université de Reims, Faculté de Pharmacie, Reims, France.
| |
Collapse
|
4
|
Rosa AC, Corsi D, Cavi N, Bruni N, Dosio F. Superoxide Dismutase Administration: A Review of Proposed Human Uses. Molecules 2021; 26:1844. [PMID: 33805942 PMCID: PMC8037464 DOI: 10.3390/molecules26071844] [Citation(s) in RCA: 55] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 03/21/2021] [Accepted: 03/22/2021] [Indexed: 12/12/2022] Open
Abstract
Superoxide dismutases (SODs) are metalloenzymes that play a major role in antioxidant defense against oxidative stress in the body. SOD supplementation may therefore trigger the endogenous antioxidant machinery for the neutralization of free-radical excess and be used in a variety of pathological settings. This paper aimed to provide an extensive review of the possible uses of SODs in a range of pathological settings, as well as describe the current pitfalls and the delivery strategies that are in development to solve bioavailability issues. We carried out a PubMed query, using the keywords "SOD", "SOD mimetics", "SOD supplementation", which included papers published in the English language, between 2012 and 2020, on the potential therapeutic applications of SODs, including detoxification strategies. As highlighted in this paper, it can be argued that the generic antioxidant effects of SODs are beneficial under all tested conditions, from ocular and cardiovascular diseases to neurodegenerative disorders and metabolic diseases, including diabetes and its complications and obesity. However, it must be underlined that clinical evidence for its efficacy is limited and consequently, this efficacy is currently far from being demonstrated.
Collapse
Affiliation(s)
- Arianna Carolina Rosa
- Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 9, 10125 Turin, Italy; (D.C.); (N.C.); (F.D.)
| | - Daniele Corsi
- Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 9, 10125 Turin, Italy; (D.C.); (N.C.); (F.D.)
| | - Niccolò Cavi
- Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 9, 10125 Turin, Italy; (D.C.); (N.C.); (F.D.)
| | - Natascia Bruni
- Istituto Farmaceutico Candioli, Strada Comunale di None, 1, 10092 Beinasco, Italy;
| | - Franco Dosio
- Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 9, 10125 Turin, Italy; (D.C.); (N.C.); (F.D.)
| |
Collapse
|
5
|
Arpicco S, Bartkowski M, Barge A, Zonari D, Serpe L, Milla P, Dosio F, Stella B, Giordani S. Effects of the Molecular Weight of Hyaluronic Acid in a Carbon Nanotube Drug Delivery Conjugate. Front Chem 2020; 8:578008. [PMID: 33381490 PMCID: PMC7767879 DOI: 10.3389/fchem.2020.578008] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 11/13/2020] [Indexed: 01/15/2023] Open
Abstract
Hyaluronic acid (HA) is a ubiquitous biopolymer involved in many pathophysiological roles. One HA receptor, the cluster of differentiation CD44 protein, is often overexpressed in tumor cells. As such, HA has attracted considerable interest in the development of drug delivery formulations, given its intrinsic targetability toward CD44 overexpressing cells. The present study is focused on examining the correlation of HA molecular weight with its targetability properties. A library of conjugates obtained by linking the amino group of the phospholipid 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE) to the carboxylic residues of HA of different molecular weight (6.4, 17, 51, 200, and 1,500 kDa) were synthesized and fully characterized. The HA-DMPE conjugates were then used to non-covalently functionalize the highly hydrophobic single-walled carbon nanotubes (CNT), and further encapsulate the anticancer drug doxorubicin (DOX). Our results show that the complexes DOX/CNT/HA-DMPE maintain very good and stable dispersibility. Drug release studies indicated a pH-responsive release of the drug from the nanocarrier. Cell viability tests demonstrated that all HA modified CNTs have good biocompatibility, and specific targeting toward cells overexpressing the CD44 receptor. Among all the molecular weights tested, the 200 kDa HA showed the highest increase in cellular uptake and cytotoxic activity. All these promising attributes make CNT/HA200-DMPE a “smart” platform for tumor-targeted delivery of anticancer agents.
Collapse
Affiliation(s)
- Silvia Arpicco
- Department of Drug Science and Technology, University of Torino, Turin, Italy
| | - Michał Bartkowski
- School of Chemical Sciences, Dublin City University (DCU), Dublin, Ireland
| | - Alessandro Barge
- Department of Drug Science and Technology, University of Torino, Turin, Italy
| | - Daniele Zonari
- Department of Drug Science and Technology, University of Torino, Turin, Italy
| | - Loredana Serpe
- Department of Drug Science and Technology, University of Torino, Turin, Italy
| | - Paola Milla
- Department of Drug Science and Technology, University of Torino, Turin, Italy
| | - Franco Dosio
- Department of Drug Science and Technology, University of Torino, Turin, Italy
| | - Barbara Stella
- Department of Drug Science and Technology, University of Torino, Turin, Italy
| | - Silvia Giordani
- School of Chemical Sciences, Dublin City University (DCU), Dublin, Ireland
| |
Collapse
|
6
|
Rosa AC, Bruni N, Meineri G, Corsi D, Cavi N, Gastaldi D, Dosio F. Strategies to expand the therapeutic potential of superoxide dismutase by exploiting delivery approaches. Int J Biol Macromol 2020; 168:846-865. [PMID: 33242550 DOI: 10.1016/j.ijbiomac.2020.11.149] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Revised: 11/04/2020] [Accepted: 11/22/2020] [Indexed: 12/18/2022]
Abstract
The overproduction of free radicals can cause oxidative-stress damage to a range of biomolecules, and thus potentially contribute to several pathologies, from neurodegenerative disorders to cardiovascular diseases and metabolic disorders. Endogenous antioxidant enzymes, such as superoxide dismutase (SOD), play an important role in diminishing oxidative stress. SOD supplementation could therefore be an effective preventive strategy to reduce the risk of free-radical overproduction. However, the efficacy of SOD administration is hampered by its rapid clearance. Several different approaches to improve the bioavailability of SOD have been explored in recent decades. This review intends to describe the rationale that underlie the various approaches and chemical strategies that have led to the most recent advances in SOD delivery. This critical description includes SOD conjugates, SOD loaded into particulate carriers (micelles, liposomes, nanoparticles, microparticles) and the most promising and suitable formulations for oral delivery, with a particular emphasis on reports of preclinical/clinical results. Likely future directions are also considered and reported.
Collapse
Affiliation(s)
| | - Natascia Bruni
- Istituto Farmaceutico Candioli Srl, Beinasco, Turin, Italy
| | - Giorgia Meineri
- Department of Veterinary Science, University of Turin, Italy
| | - Daniele Corsi
- Department of Drug Science and Technology, University of Turin, Italy
| | - Niccolò Cavi
- Department of Drug Science and Technology, University of Turin, Italy
| | - Daniela Gastaldi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
| | - Franco Dosio
- Department of Drug Science and Technology, University of Turin, Italy.
| |
Collapse
|
7
|
Ugazio E, Tullio V, Binello A, Tagliapietra S, Dosio F. Ozonated Oils as Antimicrobial Systems in Topical Applications. Their Characterization, Current Applications, and Advances in Improved Delivery Techniques. Molecules 2020; 25:E334. [PMID: 31947580 PMCID: PMC7024311 DOI: 10.3390/molecules25020334] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 01/09/2020] [Accepted: 01/11/2020] [Indexed: 12/12/2022] Open
Abstract
The search for a wide spectrum of antimicrobial agents that can avoid resistance while maintaining reasonable side effects has led to ozonated oils experiencing an increase in scientific interest and clinical applications. The treatment of vegetable oils with ozone leads to the creation of a reservoir of ozone that slowly releases into the skin thanks to the fact that ozone can be held as ozonides of unsaturated fatty acids. Interest in the use of ozonated oils has meant that several ozonated-vegetable-oil-containing products have been commercialized as cosmetic and pharmaceutical agents, and in innovative textile products with antibacterial activity. New approaches to the delivery of ozonated oils have very recently appeared in an attempt to improve their characteristics and reduce drawbacks, such as an unpleasant odor, high viscosity and undesired effects on skin, including irritation and rashes. The present review focuses on the current status of delivery agents that use ozonated oils as antimicrobial agents in topical (dermal, skin, and soft tissues) treatments. Challenges and future opportunities for these delivery systems will also be discussed.
Collapse
Affiliation(s)
- Elena Ugazio
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (E.U.); (A.B.); (S.T.)
| | - Vivian Tullio
- Department of Public Health and Pediatrics, Microbiology Division, University of Torino, 10126 Torino, Italy;
| | - Arianna Binello
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (E.U.); (A.B.); (S.T.)
| | - Silvia Tagliapietra
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (E.U.); (A.B.); (S.T.)
| | - Franco Dosio
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy; (E.U.); (A.B.); (S.T.)
| |
Collapse
|
8
|
Bosca F, Corazzari I, Foglietta F, Canaparo R, Durando G, Pastero L, Arpicco S, Dosio F, Zonari D, Cravotto G, Tagliapietra S, Serpe L, Turci F, Barge A. SWCNT–porphyrin nano-hybrids selectively activated by ultrasound: an interesting model for sonodynamic applications. RSC Adv 2020; 10:21736-21744. [PMID: 35516637 PMCID: PMC9054547 DOI: 10.1039/d0ra03944f] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Accepted: 05/29/2020] [Indexed: 11/21/2022] Open
Abstract
Sonodynamic therapy (SDT) is an innovative anticancer approach, based on the excitation of a given molecule (usually a porphyrin) by inertial acoustic cavitation that leads to cell deathviathe production of reactive oxygen species (ROS).
Collapse
Affiliation(s)
- Federica Bosca
- Department of Drug Science and Technology
- University of Turin
- Turin
- Italy
| | | | | | - Roberto Canaparo
- Department of Drug Science and Technology
- University of Turin
- Turin
- Italy
| | - Gianni Durando
- National Institute of Metrological Research (INRIM)
- Turin
- Italy
| | - Linda Pastero
- Department of Earth Sciences
- University of Turin
- Turin
- Italy
- “G. Scansetti” Interdepartmental Centre
| | - Silvia Arpicco
- Department of Drug Science and Technology
- University of Turin
- Turin
- Italy
| | - Franco Dosio
- Department of Drug Science and Technology
- University of Turin
- Turin
- Italy
| | - Daniele Zonari
- Department of Drug Science and Technology
- University of Turin
- Turin
- Italy
| | | | | | - Loredana Serpe
- Department of Drug Science and Technology
- University of Turin
- Turin
- Italy
| | - Francesco Turci
- Department of Chemistry
- University of Turin
- Turin
- Italy
- “G. Scansetti” Interdepartmental Centre
| | - Alessandro Barge
- Department of Drug Science and Technology
- University of Turin
- Turin
- Italy
| |
Collapse
|
9
|
Mougin J, Yesylevskyy SO, Bourgaux C, Chapron D, Michel JP, Dosio F, Stella B, Ramseyer C, Couvreur P. Stacking as a Key Property for Creating Nanoparticles with Tunable Shape: The Case of Squalenoyl-Doxorubicin. ACS Nano 2019; 13:12870-12879. [PMID: 31603305 DOI: 10.1021/acsnano.9b05303] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
The development of elongated nanoparticles for drug delivery is of growing interest in recent years, due to longer blood circulation and improved efficacy compared to spherical counterparts. Squalenoyl-doxorubicin (SQ-Dox) conjugate was previously shown to form elongated nanoparticles with improved therapeutic efficacy and decreased toxicity compared to free doxorubicin. By using experimental and computational techniques, we demonstrate here that the specific physical properties of SQ-Dox, which include stacking and electrostatic interactions of doxorubicin as well as hydrophobic interactions of squalene, are involved in the formation of nanoassemblies with diverse elongated structures. We show that SQ-Dox bioconjugate concentration, ionic strength, and anion nature can be used to modulate the shape and stiffness of SQ-Dox nanoparticles. As those parameters are involved in nanoparticle behavior in biological media, these findings could bring interesting opportunities for drug delivery and serve as an example for the design of original nanodrugs with stacking properties tuned for particular clinical purposes.
Collapse
Affiliation(s)
- Julie Mougin
- Institut Galien Paris-Sud UMR CNRS 8612 , Faculty of Pharmacy, Université Paris-Sud, Université Paris-Saclay , 92290 Châtenay-Malabry , France
| | - Semen O Yesylevskyy
- Department of Physics of Biological Systems , Institute of Physics of the National Academy of Sciences of Ukraine , Prospect Nauky 46 , 03028 Kyiv , Ukraine
- Laboratoire Chrono Environnement UMR CNRS 6249 , Université de Bourgogne Franche-Comté , 16 route de Gray , 25030 Besançon Cedex, France
| | - Claudie Bourgaux
- Institut Galien Paris-Sud UMR CNRS 8612 , Faculty of Pharmacy, Université Paris-Sud, Université Paris-Saclay , 92290 Châtenay-Malabry , France
| | - David Chapron
- Institut Galien Paris-Sud UMR CNRS 8612 , Faculty of Pharmacy, Université Paris-Sud, Université Paris-Saclay , 92290 Châtenay-Malabry , France
| | - Jean-Philippe Michel
- Institut Galien Paris-Sud UMR CNRS 8612 , Faculty of Pharmacy, Université Paris-Sud, Université Paris-Saclay , 92290 Châtenay-Malabry , France
| | - Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco , Università degli Studi di Torino , 10125 Turin , Italy
| | - Barbara Stella
- Dipartimento di Scienza e Tecnologia del Farmaco , Università degli Studi di Torino , 10125 Turin , Italy
| | - Christophe Ramseyer
- Laboratoire Chrono Environnement UMR CNRS 6249 , Université de Bourgogne Franche-Comté , 16 route de Gray , 25030 Besançon Cedex, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud UMR CNRS 8612 , Faculty of Pharmacy, Université Paris-Sud, Université Paris-Saclay , 92290 Châtenay-Malabry , France
| |
Collapse
|
10
|
Canaparo R, Foglietta F, Giuntini F, Della Pepa C, Dosio F, Serpe L. Recent Developments in Antibacterial Therapy: Focus on Stimuli-Responsive Drug-Delivery Systems and Therapeutic Nanoparticles. Molecules 2019; 24:E1991. [PMID: 31137622 PMCID: PMC6572634 DOI: 10.3390/molecules24101991] [Citation(s) in RCA: 103] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 05/20/2019] [Accepted: 05/22/2019] [Indexed: 12/14/2022] Open
Abstract
Conventional drugs used for antibacterial therapy display several limitations. This is not due to antibiotics being ineffective, but rather due to their low bioavailability, limited penetration to sites of infection and the rise of drug-resistant bacteria. Although new delivery systems (e.g., nanoparticles) that are loaded with antibacterial drugs have been designed to overcome these limitations, therapeutic efficacy does not seem to have improved. Against this backdrop, stimuli-responsive antibiotic-loaded nanoparticles and materials with antimicrobial properties (nanoantibiotics) present the ability to enhance therapeutic efficacy, while also reducing drug resistance and side effects. These stimuli can either be exogenous (e.g., light, ultrasound) or endogenous (e.g., pH, variation in redox gradient, enzymes). This promising therapeutic approach relies on advances in materials science and increased knowledge of microorganism growth and biofilm formation. This review provides an overview in the field of antibacterial drug-delivery systems and nanoantibiotics that benefit from a response to specific triggers, and also presents a number of future prospects.
Collapse
Affiliation(s)
- Roberto Canaparo
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
| | - Federica Foglietta
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
| | - Francesca Giuntini
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 2AJ, UK.
| | - Carlo Della Pepa
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
| | - Franco Dosio
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
| | - Loredana Serpe
- Department of Drug Science and Technology, University of Torino, 10125 Torino, Italy.
| |
Collapse
|
11
|
Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules 2018; 23:molecules23102478. [PMID: 30262735 PMCID: PMC6222489 DOI: 10.3390/molecules23102478] [Citation(s) in RCA: 156] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 09/21/2018] [Accepted: 09/25/2018] [Indexed: 01/15/2023] Open
Abstract
There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and safety. The low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration and transmucosal adsorption, being proposed. The highly lipophilic nature of cannabinoids means that they are seen as suitable candidates for advanced nanosized drug delivery systems, which can be applied via a range of routes. Nanotechnology-based drug delivery strategies have flourished in several therapeutic fields in recent years and numerous drugs have reached the market. This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment. Likely future directions are also considered and reported.
Collapse
Affiliation(s)
| | - Carlo Della Pepa
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
| | | | - Enrica Pessione
- Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy.
| | - Daniela Gastaldi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, 10125 Turin, Italy.
| | - Franco Dosio
- Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
| |
Collapse
|
12
|
Lolli ML, Sainas S, Pippione AC, Giorgis M, Boschi D, Dosio F. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy. Recent Pat Anticancer Drug Discov 2018; 13:86-105. [PMID: 29119937 DOI: 10.2174/1574892812666171108124218] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 09/27/2017] [Accepted: 10/26/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Human dihydroorotate dehydrogenase (hDHODH, EC 1.3.5.2), a flavindependent mitochondrial enzyme involved in de novo pyrimidine biosynthesis, is a validated therapeutic target for the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. However, human DHODH inhibitors have also been investigated as treatment for cancer, parasite infections (i.e. malaria) and viruses as well as in the agrochemicals industry. OBJECTIVE An overview of current knowledge of hDHODH inhibitors and their potential uses in diseases where hDHODH is involved. METHOD This review focuses on recent advances in the development and application of hDHODH inhibitors, specifically covering the patent field, starting from a brief description of enzyme topography and of the strategies usually followed in designing its selective inhibitors. RESULTS The most important and well-described novelty is the fact that the discovery, in the autumn of 2016, that hDHODH inhibitors are able to induce in vivo myeloid differentiation has led to the possibility of developing novel hDHODH based treatments for Acute Myelogenous Leukemia (AML). CONCLUSION The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target.
Collapse
Affiliation(s)
- Marco L Lolli
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin. Italy
| | - Stefano Sainas
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin. Italy
| | - Agnese C Pippione
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin. Italy
| | - Marta Giorgis
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin. Italy
| | - Donatella Boschi
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin. Italy
| | - Franco Dosio
- Department of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin. Italy
| |
Collapse
|
13
|
Fumagalli G, Giorgi G, Vágvölgyi M, Colombo E, Christodoulou MS, Collico V, Prosperi D, Dosio F, Hunyadi A, Montopoli M, Hyeraci M, Silvani A, Lesma G, Via LD, Passarella D. Heteronanoparticles by Self-Assembly of Ecdysteroid and Doxorubicin Conjugates To Overcome Cancer Resistance. ACS Med Chem Lett 2018; 9:468-471. [PMID: 29795761 PMCID: PMC5949839 DOI: 10.1021/acsmedchemlett.8b00078] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 04/17/2018] [Indexed: 12/22/2022] Open
Abstract
Heteronanoparticles (H-NPs) consisting of conjugates characterized by a squalene tail linked to doxorubicin and ecdysteroid derivatives are presented. Biological evaluation on A2780ADR cell line confirms not only the maintenance of the activity of the parental drug but also the ability to overcome cancer resistance. The in vitro cell uptake was demonstrated, and the involvement of an endosomal-mediated pathway was suggested.
Collapse
Affiliation(s)
- Gaia Fumagalli
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Giulia Giorgi
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Máté Vágvölgyi
- Szegedi Tudomanyegyetem (SZTE), Institute of Pharmacognosy, University of Szeged, 6720 Szeged, Hungary
| | - Eleonora Colombo
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Michael S Christodoulou
- DISFARM, Sezione "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Veronica Collico
- Dipartimento di Biotecnologie e Bioscienze, Università Milano Bicocca, P.zza della Scienza 2, 20126 Milano, Italy
| | - Davide Prosperi
- Dipartimento di Biotecnologie e Bioscienze, Università Milano Bicocca, P.zza della Scienza 2, 20126 Milano, Italy
| | - Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Torino 10125, Italy
| | - Attila Hunyadi
- Szegedi Tudomanyegyetem (SZTE), Institute of Pharmacognosy, University of Szeged, 6720 Szeged, Hungary
| | - Monica Montopoli
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Mariafrancesca Hyeraci
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Alessandra Silvani
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Giordano Lesma
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Lisa Dalla Via
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Daniele Passarella
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| |
Collapse
|
14
|
Abstract
Many attempts have been made to achieve good selectivity to targeted tumor cells by preparing specialized carrier agents that are therapeutically profitable for anticancer therapy. Among these, liposomes are the most studied colloidal particles thus far applied in medicine and in particular in antitumor therapy. Although they were first described in the 1960s, only at the beginning of 1990s did the first therapeutic liposomes appear on the market. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome (Nexstar, Boulder, CO, USA), used as an antifungal drug, and Myocet (Elan Pharma Int, Princeton, NJ, USA), a doxorubicin-containing liposome, used in clinical trials to treat metastatic breast cancer. The second-generation liposomes (“pure lipid approach”) were long-circulating liposomes, such as Daunoxome, a daunorubicin-containing liposome approved in the US and Europe to treat AIDS-related Kaposi's sarcoma. The third-generation liposomes were surface-modified liposomes with gangliosides or sialic acid, which can evade the immune system responsible for removing liposomes from circulation. The fourth-generation liposomes, pegylated liposomal doxorubicin, were called “stealth liposomes” because of their ability to evade interception by the immune system, in the same way as the stealth bomber was able to evade radar. Actually, the only stealth liposome on the market is Caelyx/Doxil (Schering-Plough, Madison NJ, USA), used to cure AIDS-related Kaposi's sarcoma, resistant ovarian cancer and metastatic breast cancer. Pegylated liposomal doxorubicin is characterized by a very long-circulation half-life, favorable pharmacokinetic behavior and specific accumulation in tumor tissues. These features account for the much lower toxicity shown by Caelyx in comparison to free doxorubicin, in terms of cardiotoxicity, vesicant effects, nausea, vomiting and alopecia. Pegylated liposomal doxorubicin also appeared to be less myelotoxic than doxorubicin. Typical forms of toxicity associated to it are acute infusion reaction, mucositis and palmar plantar erythrodysesthesia, which occur especially at high doses or short dosing intervals. Active and cell targeted liposomes can be obtained by attaching some antigen-directed monoclonal antibodies (Moab or Moab fragments) or small proteins and molecules (folate, epidermal growth factor, transferrin) to the distal end of polyethylene glycol in pegylated liposomal doxorubicin. The most promising therapeutic application of liposomes is as non-viral vector agents in gene therapy, characterized by the use of cationic phospholipids complexed with the negatively charged DNA plasmid. The use of liposome formulations in local-regional anticancer therapy is also discussed. Finally, pegylated liposomal doxorubicin containing radionuclides are used in clinical trials as tumor-imaging agents or in positron emission tomography.
Collapse
Affiliation(s)
- Luigi Cattel
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Italy.
| | | | | |
Collapse
|
15
|
Turino LN, Stella B, Dosio F, Luna JA, Barresi AA. Nanoparticles obtained by confined impinging jet mixer: poly(lactide-co-glycolide) vs. Poly-ε-caprolactone. Drug Dev Ind Pharm 2018; 44:934-941. [DOI: 10.1080/03639045.2017.1421662] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Ludmila N. Turino
- Dipartimento di Scienza Applicata e Tecnologia, Politecnico di Torino, Torino, Italy
- Laboratorio de Química Fina. Instituto de Desarrollo Tecnológico para la Industria Química (INTEC), Universidad Nacional del Litoral (UNL), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Santa Fe, Argentina
| | - Barbara Stella
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Torino, Italy
| | - Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Torino, Italy
| | - Julio A. Luna
- Laboratorio de Química Fina. Instituto de Desarrollo Tecnológico para la Industria Química (INTEC), Universidad Nacional del Litoral (UNL), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Santa Fe, Argentina
| | - Antonello A. Barresi
- Dipartimento di Scienza Applicata e Tecnologia, Politecnico di Torino, Torino, Italy
| |
Collapse
|
16
|
Sainas S, Pippione A, Boschi D, Gaidano V, Circosta P, Cignetti A, Dosio F, Lolli M. DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.11.2856492] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Fumagalli G, Stella B, Pastushenko I, Ricci F, Christodoulou MS, Damia G, Mazza D, Arpicco S, Giannini C, Morosi L, Dosio F, Sotiropoulou PA, Passarella D. Heteronanoparticles by self-Assembly of Doxorubicin and Cyclopamine Conjugates. ACS Med Chem Lett 2017; 8:953-957. [PMID: 28947943 PMCID: PMC5601370 DOI: 10.1021/acsmedchemlett.7b00262] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 08/01/2017] [Indexed: 11/29/2022] Open
Abstract
The preparation of heteronanoparticles (NPs) with doxorubicin (DOXO) and cyclopamine (CYP) conjugates is presented. Biological evaluation on A431 cell lines confirms the maintenance of the activity of the parental drugs. The in vivo study shows that self-assembled NPs reduce tumor growth and toxicity of chemotherapy.
Collapse
Affiliation(s)
- Gaia Fumagalli
- Dipartimento
di Chimica, Università degli Studi
di Milano, Milano 20133, Italy
| | - Barbara Stella
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università
degli Studi di Torino, Torino 10125, Italy
| | - Ievgenia Pastushenko
- Interdisciplinary
Research Institute (IRIBHM), Université
Libre de Bruxelles (ULB), Brussels 1070, Belgium
| | - Francesca Ricci
- Laboratory
of Molecular Pharmacology, IRCCS-Istituto
di Ricerche Farmacologiche Mario Negri, Milano 20156, Italy
| | | | - Giovanna Damia
- Laboratory
of Molecular Pharmacology, IRCCS-Istituto
di Ricerche Farmacologiche Mario Negri, Milano 20156, Italy
| | - Davide Mazza
- Centro
di Imaging Sperimentale San Raffaele Scientific Institute, Milano 20132, Italy
- Centro
Europeo di Nanomedicina, Milano 20133, Italy
| | - Silvia Arpicco
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università
degli Studi di Torino, Torino 10125, Italy
| | - Clelia Giannini
- Dipartimento
di Chimica, Università degli Studi
di Milano, Milano 20133, Italy
| | - Lavinia Morosi
- Laboratory
of Cancer Pharmacology, IRCCS-Istituto di
Ricerche Farmacologiche Mario Negri, Milano 20156, Italy
| | - Franco Dosio
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università
degli Studi di Torino, Torino 10125, Italy
| | - Panagiota A. Sotiropoulou
- Interdisciplinary
Research Institute (IRIBHM), Université
Libre de Bruxelles (ULB), Brussels 1070, Belgium
| | - Daniele Passarella
- Dipartimento
di Chimica, Università degli Studi
di Milano, Milano 20133, Italy
| |
Collapse
|
18
|
Bruni N, Stella B, Giraudo L, Della Pepa C, Gastaldi D, Dosio F. Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomedicine 2017; 12:5289-5311. [PMID: 28794624 PMCID: PMC5536235 DOI: 10.2147/ijn.s140363] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the genus Leishmania, which are responsible for numerous clinical manifestations, such as cutaneous, visceral, and mucocutaneous leishmaniasis, depending on the site of infection for particular species. These complexities threaten 350 million people in 98 countries worldwide. Amastigotes living within macrophage phagolysosomes are the principal target of antileishmanial treatment, but these are not an easy target as drugs must overcome major structural barriers. Furthermore, limitations on current therapy are related to efficacy, toxicity, and cost, as well as the length of treatment, which can increase parasitic resistance. Nanotechnology has emerged as an attractive alternative as conventional drugs delivered by nanosized carriers have improved bioavailability and reduced toxicity, together with other characteristics that help to relieve the burden of this disease. The significance of using colloidal carriers loaded with active agents derives from the physiological uptake route of intravenous administered nanosystems (the phagocyte system). Nanosystems are thus able to promote a high drug concentration in intracellular mononuclear phagocyte system (MPS)-infected cells. Moreover, the versatility of nanometric drug delivery systems for the deliberate transport of a range of molecules plays a pivotal role in the design of therapeutic strategies against leishmaniasis. This review discusses studies on nanocarriers that have greatly contributed to improving the efficacy of antileishmaniasis drugs, presenting a critical review and some suggestions for improving drug delivery.
Collapse
Affiliation(s)
| | - Barbara Stella
- Department of Drug Science and Technology, University of Turin, Turin, Italy
| | | | - Carlo Della Pepa
- Department of Drug Science and Technology, University of Turin, Turin, Italy
| | - Daniela Gastaldi
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
| | - Franco Dosio
- Department of Drug Science and Technology, University of Turin, Turin, Italy
| |
Collapse
|
19
|
Biasibetti E, Corona A, Valenza F, Dosio F, Bruni N, Capucchio M. Antifungal Susceptibility of Canine and Feline Malassezia spp. Isolates to Lactoferricin: Preliminary In-Vitro Study. J Comp Pathol 2017. [DOI: 10.1016/j.jcpa.2016.11.136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Fumagalli G, Marucci C, Christodoulou MS, Stella B, Dosio F, Passarella D. Self-assembly drug conjugates for anticancer treatment. Drug Discov Today 2016; 21:1321-9. [DOI: 10.1016/j.drudis.2016.06.018] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Revised: 05/10/2016] [Accepted: 06/15/2016] [Indexed: 12/28/2022]
|
21
|
Bruni N, Capucchio MT, Biasibetti E, Pessione E, Cirrincione S, Giraudo L, Corona A, Dosio F. Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine. Molecules 2016; 21:E752. [PMID: 27294909 PMCID: PMC6273662 DOI: 10.3390/molecules21060752] [Citation(s) in RCA: 122] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 06/03/2016] [Accepted: 06/06/2016] [Indexed: 01/15/2023] Open
Abstract
Antimicrobial peptides (AMPs) represent a vast array of molecules produced by virtually all living organisms as natural barriers against infection. Among AMP sources, an interesting class regards the food-derived bioactive agents. The whey protein lactoferrin (Lf) is an iron-binding glycoprotein that plays a significant role in the innate immune system, and is considered as an important host defense molecule. In search for novel antimicrobial agents, Lf offers a new source with potential pharmaceutical applications. The Lf-derived peptides Lf(1-11), lactoferricin (Lfcin) and lactoferrampin exhibit interesting and more potent antimicrobial actions than intact protein. Particularly, Lfcin has demonstrated strong antibacterial, anti-fungal and antiparasitic activity with promising applications both in human and veterinary diseases (from ocular infections to osteo-articular, gastrointestinal and dermatological diseases).
Collapse
Affiliation(s)
- Natascia Bruni
- Istituto Farmaceutico Candioli, Beinasco (To) 10092, Italy.
| | | | - Elena Biasibetti
- Department of Veterinary Sciences, University of Torino, Torino 10095, Italy.
| | - Enrica Pessione
- Department of Life Sciences and Systems Biology, University of Torino, Torino 10123, Italy.
| | - Simona Cirrincione
- Department of Life Sciences and Systems Biology, University of Torino, Torino 10123, Italy.
| | | | | | - Franco Dosio
- Department of Drug Science and Technology, University of Torino, Torino 10125, Italy.
| |
Collapse
|
22
|
Arpicco S, Battaglia L, Brusa P, Cavalli R, Chirio D, Dosio F, Gallarate M, Milla P, Peira E, Rocco F, Sapino S, Stella B, Ugazio E, Ceruti M. Recent studies on the delivery of hydrophilic drugs in nanoparticulate systems. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2015.09.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
23
|
Dosio F, Arpicco S, Stella B, Fattal E. Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 2016; 97:204-36. [PMID: 26592477 DOI: 10.1016/j.addr.2015.11.011] [Citation(s) in RCA: 388] [Impact Index Per Article: 48.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 11/03/2015] [Accepted: 11/04/2015] [Indexed: 01/06/2023]
Abstract
Hyaluronic acid (HA) is widely used in anticancer drug delivery, since it is biocompatible, biodegradable, non-toxic, and non-immunogenic; moreover, HA receptors are overexpressed on many tumor cells. Exploiting this ligand-receptor interaction, the use of HA is now a rapidly-growing platform for targeting CD44-overexpressing cells, to improve anticancer therapies. The rationale underlying approaches, chemical strategies, and recent advances in the use of HA to design drug carriers for delivering anticancer agents, are reviewed. Comprehensive descriptions are given of HA-based drug conjugates, particulate carriers (micelles, liposomes, nanoparticles, microparticles), inorganic nanostructures, and hydrogels, with particular emphasis on reports of preclinical/clinical results.
Collapse
|
24
|
Fumagalli G, Mazza D, Christodoulou MS, Damia G, Ricci F, Perdicchia D, Stella B, Dosio F, Sotiropoulou PA, Passarella D. Cyclopamine-Paclitaxel-Containing Nanoparticles: Internalization in Cells Detected by Confocal and Super-Resolution Microscopy. Chempluschem 2015; 80:1380-1383. [DOI: 10.1002/cplu.201500156] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Indexed: 12/17/2022]
|
25
|
Soria F, Milla P, Fiorito C, Pisano F, Sogni F, Di Marco M, Pagliarulo V, Dosio F, Gontero P. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study. World J Urol 2015; 34:189-95. [PMID: 26026818 DOI: 10.1007/s00345-015-1595-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Accepted: 05/16/2015] [Indexed: 11/29/2022] Open
Abstract
PURPOSE We report for the first time the activity and safety of Unithermia(®) (Elmedical Ltd, Hod-Hasharon, Israel), a novel device for administration of MMC-C with hyperthermia (HT), that employs conductive heating, in a series of non-grade 3 non-muscle-invasive bladder cancer (NMIBC) that failed Bacillus Calmette-Guerin (BCG). METHODS Patients with non-grade 3 NMIBC recurring after at least a full induction course of BCG were eligible for this phase I-II prospective single-arm study. Six weekly instillations with Unithermia(®) were scheduled following complete TUR. Primary end points were treatment safety and response rate (RR), and the latter defined as the absence of any unfavourable outcome at 12 months. Any grade 3 and/or muscle-invasive (T > 1) recurrence was considered disease progression. Kaplan-Meier estimation of the time to recurrence and progression, cancer-specific survival and overall survival was taken as secondary end points. RESULTS Thirty-four eligible patients entered the study between January 2009 and April 2011. RR was documented in 20/34 (59%). Among the 14/34 (41%) non-responders, four developed G3 disease, one developed carcinoma in situ, and one progressed to muscle-invasive bladder cancer, with an overall 18% progression rate at 1 year. At a median follow-up of 41 months, recurrence and progression rates were 35.3 and 23.5%, respectively. Toxicity did not go beyond grade 2 except in five cases. CONCLUSIONS Initial experience with MMC-HT with Unithermia(®) showed an interesting activity and safety profile in non-grade 3 NMIBC recurring after BCG, suggesting a role as second-line therapy in this selected subgroup of NMIBC.
Collapse
Affiliation(s)
- Francesco Soria
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, C.so Bramante 88/90, 10126, Turin, Italy
| | - Paola Milla
- Department of Pharmacology, University of Studies of Torino, Turin, Italy
| | - Chiara Fiorito
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, C.so Bramante 88/90, 10126, Turin, Italy
| | - Francesca Pisano
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, C.so Bramante 88/90, 10126, Turin, Italy
| | - Filippo Sogni
- Urology Clinic, Maggiore della Carità Hospital, Novara, Italy
| | | | | | - Franco Dosio
- Department of Pharmacology, University of Studies of Torino, Turin, Italy
| | - Paolo Gontero
- Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, C.so Bramante 88/90, 10126, Turin, Italy.
| |
Collapse
|
26
|
Pippione AC, Dosio F, Ducime A, Federico A, Martina K, Sainas S, Frølund B, Gooyit M, Janda KD, Boschi D, Lolli ML. Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches. Med Chem Commun 2015. [DOI: 10.1039/c5md00182j] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The hydroxytriazole system is here analysed and used to modulate acidic moieties present in lead compounds.
Collapse
|
27
|
Valetti S, Mura S, Noiray M, Arpicco S, Dosio F, Vergnaud J, Desmaële D, Stella B, Couvreur P. Peptide Conjugation: Before or After Nanoparticle Formation? Bioconjug Chem 2014; 25:1971-83. [DOI: 10.1021/bc5003423] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Sabrina Valetti
- Université Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
- CNRS UMR 8612, Institut Galien Paris-Sud, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università di Torino, 9 via Pietro
Giuria, 10125 Torino, Italy
| | - Simona Mura
- Université Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
- CNRS UMR 8612, Institut Galien Paris-Sud, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
| | - Magali Noiray
- Université Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
- CNRS UMR 8612, Institut Galien Paris-Sud, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
| | - Silvia Arpicco
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università di Torino, 9 via Pietro
Giuria, 10125 Torino, Italy
| | - Franco Dosio
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università di Torino, 9 via Pietro
Giuria, 10125 Torino, Italy
| | - Juliette Vergnaud
- Université Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
- CNRS UMR 8612, Institut Galien Paris-Sud, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
| | - Didier Desmaële
- Université Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
- CNRS UMR 8612, Institut Galien Paris-Sud, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
| | - Barbara Stella
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università di Torino, 9 via Pietro
Giuria, 10125 Torino, Italy
| | - Patrick Couvreur
- Université Paris-Sud, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
- CNRS UMR 8612, Institut Galien Paris-Sud, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry cedex, France
| |
Collapse
|
28
|
Borrelli S, Cartelli D, Secundo F, Fumagalli G, Christodoulou MS, Borroni A, Perdicchia D, Dosio F, Milla P, Cappelletti G, Passarella D. Self‐Assembled Squalene‐based Fluorescent Heteronanoparticles. Chempluschem 2014. [DOI: 10.1002/cplu.201402239] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Stella Borrelli
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano (Italy), Fax: (+39) 0250314078
| | - Daniele Cartelli
- Dipartimento di Bioscienze, Università degli Studi di Milano, Via Celoria 26, 20133 Milano (Italy)
| | - Francesco Secundo
- Istituto di Chimica del Riconoscimento Molecolare, Consiglio Nazionale delle Ricerche (CNR), Via Mario Bianco, 9, 20131 Milano (Italy)
| | - Gaia Fumagalli
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano (Italy), Fax: (+39) 0250314078
| | - Michael S. Christodoulou
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano (Italy), Fax: (+39) 0250314078
| | - Ambra Borroni
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano (Italy), Fax: (+39) 0250314078
| | - Dario Perdicchia
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano (Italy), Fax: (+39) 0250314078
| | - Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Giuria 9, 10125 Torino (Italy)
| | - Paola Milla
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Giuria 9, 10125 Torino (Italy)
| | - Graziella Cappelletti
- Dipartimento di Bioscienze, Università degli Studi di Milano, Via Celoria 26, 20133 Milano (Italy)
| | - Daniele Passarella
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano (Italy), Fax: (+39) 0250314078
| |
Collapse
|
29
|
Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, Gallarate M, Dosio F. Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art. Eur J Pharm Biopharm 2014; 87:433-44. [DOI: 10.1016/j.ejpb.2014.05.004] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Revised: 04/29/2014] [Accepted: 05/02/2014] [Indexed: 12/11/2022]
|
30
|
Borrelli S, Christodoulou MS, Ficarra I, Silvani A, Cappelletti G, Cartelli D, Damia G, Ricci F, Zucchetti M, Dosio F, Passarella D. New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A. Eur J Med Chem 2014; 85:179-90. [PMID: 25084144 DOI: 10.1016/j.ejmech.2014.07.035] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Revised: 05/09/2014] [Accepted: 07/10/2014] [Indexed: 12/23/2022]
Abstract
The present study reports the preparation of a novel class of squalene conjugates with paclitaxel, podophyllotoxin, camptothecin and epothilone A. The obtained compounds are characterized by a squalene tail that makes them able to self-assemble in water, and by a drug unit connected via a disulfide-containing linker to secure the release inside the cell. All the obtained compounds were effectively able to self-assemble and to release the parent drug in vitro. Disulfide-containing paclitaxel-squalene derivative showed a similar biological activity when compared to the free drug. Immunofluorescence assay shows that this squalene conjugate enters A549 cells and stain microtubule bundles. The results described herein pave the way for different classes of squalene-based releasable nanoassemblies.
Collapse
Affiliation(s)
- Stella Borrelli
- Dipartimento di Chimica, Università degli Studi di Milano, Via C. Golgi 19, 20133 Milano, Italy
| | - Michael S Christodoulou
- Dipartimento di Chimica, Università degli Studi di Milano, Via C. Golgi 19, 20133 Milano, Italy
| | - Ilaria Ficarra
- Dipartimento di Chimica, Università degli Studi di Milano, Via C. Golgi 19, 20133 Milano, Italy
| | - Alessandra Silvani
- Dipartimento di Chimica, Università degli Studi di Milano, Via C. Golgi 19, 20133 Milano, Italy
| | - Graziella Cappelletti
- Dipartimento di Bioscienze, Università degli Studi di Milano, Via Celoria 26, 20133 Milano, Italy
| | - Daniele Cartelli
- Dipartimento di Bioscienze, Università degli Studi di Milano, Via Celoria 26, 20133 Milano, Italy
| | - Giovanna Damia
- Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy
| | - Francesca Ricci
- Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy
| | - Massimo Zucchetti
- Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy
| | - Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco, Via Giuria 9, 10125 Torino, Italy
| | - Daniele Passarella
- Dipartimento di Chimica, Università degli Studi di Milano, Via C. Golgi 19, 20133 Milano, Italy.
| |
Collapse
|
31
|
Arpicco S, Milla P, Stella B, Dosio F. Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment. Molecules 2014; 19:3193-230. [PMID: 24642908 PMCID: PMC6271549 DOI: 10.3390/molecules19033193] [Citation(s) in RCA: 86] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Revised: 03/07/2014] [Accepted: 03/11/2014] [Indexed: 12/13/2022] Open
Abstract
Hyaluronic acid (HA) is a naturally-occurring glycosaminoglycan and a major component of the extracellular matrix. Low levels of the hyaluronic acid receptor CD44 are found on the surface of epithelial, hematopoietic, and neuronal cells; it is overexpressed in many cancer cells, and in particular in tumor-initiating cells. HA has recently attracted considerable interest in the field of developing drug delivery systems, having been used, as such or encapsulated in different types of nanoassembly, as ligand to prepare nano-platforms for actively targeting drugs, genes, and diagnostic agents. This review describes recent progress made with the several chemical strategies adopted to synthesize conjugates and prepare novel delivery systems with improved behaviors.
Collapse
Affiliation(s)
- Silvia Arpicco
- Dipartimento di Scienza e Tecnologia del Farmaco (Department of Drug Science and Technology), University of Torino, Torino, I-10125, Italy
| | - Paola Milla
- Dipartimento di Scienza e Tecnologia del Farmaco (Department of Drug Science and Technology), University of Torino, Torino, I-10125, Italy
| | - Barbara Stella
- Dipartimento di Scienza e Tecnologia del Farmaco (Department of Drug Science and Technology), University of Torino, Torino, I-10125, Italy
| | - Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco (Department of Drug Science and Technology), University of Torino, Torino, I-10125, Italy.
| |
Collapse
|
32
|
Serpe L, Gallicchio M, Canaparo R, Dosio F. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmgenomics Pers Med 2014; 7:31-42. [PMID: 24516337 PMCID: PMC3917542 DOI: 10.2147/pgpm.s58374] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Among the gynecological malignancies, ovarian cancer is the leading cause of mortality in developed countries. Treatment of ovarian cancer is based on surgery integrated with chemotherapy. Platinum-based drugs (cisplatin and carboplatin) comprise the core of first-line chemotherapy for patients with advanced ovarian cancer. Platinum-resistant ovarian cancer can be treated with cytotoxic chemotherapeutics such as paclitaxel, topotecan, PEGylated liposomal doxorubicin, or gemcitabine, but many patients eventually relapse on treatment. Targeted therapies based on agents specifically directed to overexpressed receptors, or to selected molecular targets, may be the future of clinical treatment. In this regard, overexpression of folate receptor-α on the surface of almost all epithelial ovarian cancers makes this receptor an excellent "tumor-associated antigen". With appropriate use of spacers/linkers, folate-targeted drugs can be distributed within the body, where they preferentially bind to ovarian cancer cells and are released inside their target cells. Here they can exert their desired cytotoxic function. Based on this strategy, 12 years after it was first described, a folate-targeted vinblastine derivative has now reached Phase III clinical trials in ovarian cancer. This review examines the importance of folate targeting, the state of the art of a vinblastine folate-targeted agent (vintafolide) for treating platinum-resistant ovarian cancer, and its diagnostic companion (etarfolatide) as a prognostic agent. Etarfolatide is a valuable noninvasive diagnostic imaging agent with which to select ovarian cancer patient populations that may benefit from this specific targeted therapy.
Collapse
Affiliation(s)
- Loredana Serpe
- Department of Drug Science and Technology, University of Turin, Italy
| | | | - Roberto Canaparo
- Department of Drug Science and Technology, University of Turin, Italy
| | - Franco Dosio
- Department of Drug Science and Technology, University of Turin, Italy
| |
Collapse
|
33
|
Abstract
In this review, the different types of liposome used in medicine, in particular in the field of antitumor therapy, are focalised, emphasizing their structures, pharmacological action, pharmacokinetics and biodistribution, toxicity profiles and in the main clinical applications. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and Myocet, doxorubicin-containing liposome used in clinical trials to treat metastatic breast cancer. The last generation liposomes were pegylated liposomal doxorubicin (Caelix), called "stealth liposomes" because of their ability to evade interception by the immune system, characterized by very long-circulation half-life, favourable pharmacokinetic behaviour and specific accumulation in tumor tissues.
Collapse
Affiliation(s)
- L Cattel
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria 9, 10125 Torino, Italy.
| | | | | |
Collapse
|
34
|
Dosio F, Stella B, Cerioni S, Gastaldi D, Arpicco S. Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins. Recent Pat Anticancer Drug Discov 2013; 9:35-65. [DOI: 10.2174/15748928113089990045] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 02/21/2013] [Accepted: 03/07/2013] [Indexed: 11/22/2022]
|
35
|
Dosio F, Stella B, Ferrero A, Garino C, Zonari D, Arpicco S, Cattel L, Giordano S, Gobetto R. Ruthenium polypyridyl squalene derivative: A novel self-assembling lipophilic probe for cellular imaging. Int J Pharm 2013; 440:221-8. [DOI: 10.1016/j.ijpharm.2012.07.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Revised: 07/08/2012] [Accepted: 07/13/2012] [Indexed: 10/28/2022]
|
36
|
Sarpietro MG, Ottimo S, Paolino D, Ferrero A, Dosio F, Castelli F. Squalenoyl prodrug of paclitaxel: Synthesis and evaluation of its incorporation in phospholipid bilayers. Int J Pharm 2012; 436:135-40. [DOI: 10.1016/j.ijpharm.2012.06.034] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2012] [Revised: 06/11/2012] [Accepted: 06/12/2012] [Indexed: 11/30/2022]
|
37
|
Arpicco S, Dosio F, Stella B, Cattel L. Anticancer prodrugs: an overview of major strategies and recent developments. Curr Top Med Chem 2012; 11:2346-81. [PMID: 21671864 DOI: 10.2174/156802611797183221] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2010] [Revised: 06/07/2010] [Accepted: 06/11/2010] [Indexed: 11/22/2022]
Abstract
Research in anticancer chemotherapy has produced outstanding results, and mean survival rates have significantly improved over the last ten years. Nevertheless, all approved drugs are still characterized by narrow therapeutic windows that result mainly from their high systemic toxicity combined with their marked lack of tumor selectivity. Medicinal chemistry responds to the resulting demands with new analogues of a lead drug, or by developing prodrugs. Prodrugs are inactive compounds, which are metabolized in the body, either chemically or enzymatically, in a controlled or predictable manner, to the active parent drug. This review describes the results of strategies in prodrug development, subdivided into the principal categories of anticancer agents. The chemical implementation of prodrug approaches is illustrated through selected drug candidates.
Collapse
Affiliation(s)
- Silvia Arpicco
- Universita degli Studi di Torino, Facolta di Farmacia, Dipartimento di Scienza e Tecnologia del Farmaco, Via P. Giuria 9, 10125 Torino, Italy.
| | | | | | | |
Collapse
|
38
|
Valente I, Stella B, Marchisio DL, Dosio F, Barresi AA. Production of PEGylated Nanocapsules through Solvent Displacement in Confined Impinging Jet Mixers. J Pharm Sci 2012; 101:2490-501. [DOI: 10.1002/jps.23167] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2011] [Revised: 02/02/2012] [Accepted: 04/05/2012] [Indexed: 11/12/2022]
|
39
|
Milla P, Dosio F, Cattel L. PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery. Curr Drug Metab 2012; 13:105-19. [PMID: 21892917 DOI: 10.2174/138920012798356934] [Citation(s) in RCA: 269] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2011] [Revised: 04/11/2011] [Accepted: 09/19/2011] [Indexed: 11/22/2022]
|
40
|
Lince F, Bolognesi S, Stella B, Marchisio DL, Dosio F. Preparation of polymer nanoparticles loaded with doxorubicin for controlled drug delivery. Chem Eng Res Des 2011. [DOI: 10.1016/j.cherd.2011.03.010] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 2011; 3:848-83. [PMID: 22069744 PMCID: PMC3202854 DOI: 10.3390/toxins3070848] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2011] [Revised: 07/02/2011] [Accepted: 07/06/2011] [Indexed: 12/02/2022] Open
Abstract
Immunotoxins and antibody-drug conjugates are protein-based drugs combining a target-specific binding domain with a cytotoxic domain. Such compounds are potentially therapeutic against diseases including cancer, and several clinical trials have shown encouraging results. Although the targeted elimination of malignant cells is an elegant concept, there are numerous practical challenges that limit conjugates’ therapeutic use, including inefficient cellular uptake, low cytotoxicity, and off-target effects. During the preparation of immunoconjugates by chemical synthesis, the choice of the hinge component joining the two building blocks is of paramount importance: the conjugate must remain stable in vivo but must afford efficient release of the toxic moiety when the target is reached. Vast efforts have been made, and the present article reviews strategies employed in developing immunoconjugates, focusing on the evolution of chemical linkers.
Collapse
Affiliation(s)
- Franco Dosio
- Department of Drug Science and Technology, University of Torino, Torino 10125, Italy.
| | | | | |
Collapse
|
42
|
Arias JL, Reddy LH, Othman M, Gillet B, Desmaële D, Zouhiri F, Dosio F, Gref R, Couvreur P. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano 2011; 5:1513-21. [PMID: 21275408 DOI: 10.1021/nn1034197] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
This study reports the design of a novel theragnostic nanomedicine which combines (i) the ability to target a prodrug of gemcitabine to an experimental solid tumor under the influence of a magnetic field with (ii) the imaging of the targeted tumoral nodule. This concept is based on the inclusion of magnetite nanocrystals into nanoparticles (NPs) constructed by self-assembling molecules of the squalenoyl gemcitabine (SQgem) bioconjugate. The nanocomposites are characterized by an unusually high drug loading, a significant magnetic susceptibility, and a low burst release. When injected to the L1210 subcutaneous mice tumor model, these magnetite/SQgem NPs were magnetically guided, and they displayed considerably greater anticancer activity than the other anticancer treatments (magnetite/SQgem NPs nonmagnetically guided, SQgem NPs, or gemcitabine free in solution). The histology and immunohistochemistry investigation of the tumor biopsies clearly evidenced the therapeutic superiority of the magnetically guided nanocomposites, while Prussian blue staining confirmed their accumulation at the tumor periphery. The superior therapeutic activity and enhanced tumor accumulation has been successfully visualized using T(2)-weighted imaging in magnetic resonance imaging (MRI). This concept was further enlarged by (i) the design of squalene-based NPs containing the T(1) Gd(3+) contrast agent instead of magnetite and (ii) the application to other anticancer squalenoyls, such as, cisplatin, doxorubicin, and paclitaxel. Thus, by combining different anticancer medicines as well as contrast imaging agents in NPs, we open the door toward generic conceptual framework for cancer treatment and diagnosis. This new theragnostic nanotechnology platform is expected to have important applications in cancer therapy.
Collapse
Affiliation(s)
- José L Arias
- Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Granada, 18071-Granada, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Lince F, Bolognesi S, Marchisio DL, Stella B, Dosio F, Barresi AA, Cattel L. Preparation of poly(MePEGCA-co-HDCA) nanoparticles with confined impinging jets reactor: experimental and modeling study. J Pharm Sci 2011; 100:2391-405. [PMID: 21259236 DOI: 10.1002/jps.22451] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Revised: 06/23/2010] [Accepted: 11/18/2010] [Indexed: 11/05/2022]
Abstract
In this work, the biodegradable copolymer poly(methoxypolyethyleneglycolcyanoacrylate-co-hexadecylcyanoacrylate) is used to prepare nanoparticles via solvent displacement in a confined impinging jets reactor (CIJR). For comparison, nanoparticles constituted by the homopolymer counterpart are also investigated. The CIJR is a small passive mixer in which very fast turbulent mixing of the solvent (i.e., acetone and tetrahydrofuran) and of the antisolvent (i.e., water) solutions occurs under controlled conditions. The effect of the initial copolymer concentration, solvent type, antisolvent-to-solvent ratio, and mixing rate inside the mixer on the final nanoparticle size distribution, surface properties, and morphology is investigated from the experimental point of view. The effect of some of these parameters is studied by means of a computational fluid dynamics (CFD) model, capable of quantifying the mixing conditions inside the CIJR. Results show that the CIJR can be profitably used for producing nanoparticles with controlled characteristics, that there is a clear correlation between the mixing rate calculated by CFD and the mean nanoparticle size, and therefore that CFD can be used to design, optimize, and scale-up these processes.
Collapse
Affiliation(s)
- Federica Lince
- Dipartimento di Scienza dei Materiali e Ingegneria Chimica, Politecnico di Torino, Torino 10129, Italy
| | | | | | | | | | | | | |
Collapse
|
44
|
|
45
|
Dosio F, Milla P, Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 2010; 11:1424-1433. [PMID: 21154124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
EC-145, under development by Endocyte, is a conjugate composed of desacetylvinblastine monohydrazide linked through a peptide spacer to the targeting moiety folic acid, for the potential intravenous treatment of folate receptor-overexpressing tumors, in particular ovarian and lung cancers. In vitro studies demonstrated that EC-145 selectively binds to cells that overexpress the folate receptor, causing dose-dependent cytotoxicity. Furthermore, coincubation of the KB human nasopharyngeal carcinoma cell line with EC-145 and doxorubicin resulted in synergistic antitumor activity. Experiments in mouse tumor xenograft models have confirmed the potency of EC-145 and the curative effects of the drug conjugate were demonstrated in an aggressive lymphoma xenograft model. In a phase I clinical trial in patients with advanced or metastatic solid tumors, adverse events were generally of moderate severity with the most frequent being fatigue, constipation and peripheral sensory neuropathy. Preliminary data from a phase II clinical trial in patients with advanced ovarian cancer demonstrated that third- or fourth-line treatment with EC-145 yielded better disease control than second- or third-line liposomal doxorubicin. Coadministration of EC-145 and liposomal doxorubicin produced a statistically significant increase in progression-free survival over standard therapy in patients with platinum-resistant ovarian cancer. Phase III clinical trials are expected to confirm these promising results.
Collapse
Affiliation(s)
- Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria 9, Turin, Italy.
| | | | | |
Collapse
|
46
|
Dosio F, Reddy LH, Ferrero A, Stella B, Cattel L, Couvreur P. Novel Nanoassemblies Composed of Squalenoyl−Paclitaxel Derivatives: Synthesis, Characterization, and Biological Evaluation. Bioconjug Chem 2010; 21:1349-61. [DOI: 10.1021/bc100154g] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Dosio F, Arpicco S, Stella B, Brusa P, Cattel L. Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int J Pharm 2009; 382:117-23. [DOI: 10.1016/j.ijpharm.2009.08.018] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2009] [Revised: 08/13/2009] [Accepted: 08/16/2009] [Indexed: 10/20/2022]
|
48
|
Norez C, Pasetto M, Dechecchi MC, Barison E, Anselmi C, Tamanini A, Quiri F, Cattel L, Rizzotti P, Dosio F, Cabrini G, Colombatti M. Chemical conjugation of ΔF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl−channel functions. Am J Physiol Lung Cell Mol Physiol 2008; 295:L336-47. [DOI: 10.1152/ajplung.00059.2008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The most common mutation of the cystic fibrosis (CF) gene, the deletion of Phe508, encodes a protein (ΔF508-CFTR) that fails to fold properly, thus mutated ΔF508-cystic fibrosis transmembrane conductance regulator (CFTR) is recognized and degraded via the ubiquitin-proteasome endoplasmic reticulum-associated degradation pathway. Chemical and pharmacological chaperones and ligand-induced transport open options for designing specific drugs to control protein (mis)folding or transport. A class of compounds that has been proposed as having potential utility in ΔF508-CFTR is that which targets the molecular chaperone and proteasome systems. In this study, we have selected deoxyspergualin (DSG) as a reference molecule for this class of compounds and for ease of cross-linking to human serum albumin (HSA) as a protein transporter. Chemical cross-linking of DSG to HSA via a disulfide-based cross-linker and its administration to cells carrying ΔF508-CFTR resulted in a greater enhancement of ΔF508-CFTR function than when free DSG was used. Function of the selenium-dependent oxidoreductase system was required to allow intracellular activation of HSA-DSG conjugates. The principle that carrier proteins can deliver pharmacological chaperones to cells leading to correction of defective CFTR functions is therefore proven and warrants further investigations.
Collapse
|
49
|
Airoldi M, Cattel L, Milla P, Pedani F, Garzaro M, Dosio F. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. Anticancer Res 2008; 28:2519-2527. [PMID: 18751444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND The combination of paclitaxel (PTX) with pegylated liposomal doxorubicin (PLD) is an interesting treatment for recurrent head and neck cancer. The pharmacokinetic behavior may depend on the interval between the intravenous administration of the two drugs. This study evaluates the clinical efficacy, toxicity and any possible interval-dependent pharmacokinetic interactions. PATIENTS AND METHODS Thirty patients were randomized to receive 80 mg/m2 PTX weekly and 12.5 mg/m2 PLD every two weeks at administration intervals of 0, 1, 3, 12 or 24 hours. Blood sampling was performed at day 1 and 15 and pharmacokinetics of PTX, PLD and Cremophor EL were evaluated by non-compartmental analysis. RESULTS Neutropenia was the most frequent side-effect (100% of patients; 30% grade 3-4). Hand-foot syndrome was severe in only 3% of patients. Overall response rate was 30%, with 3% complete responses and 27% partial responses. Stable disease and progression were 43% and 27%, respectively. Median response duration and overall median survival were 5.5 and 10 months respectively. Co-administration of PLD markedly reduced Cmax and the area under the curve (AUC), and increased PTX clearance. The differences in the PTX AUC and clearance between the 0 h and the 24 h experimental arms were statistically significant. CONCLUSION The PTX/PLD combination plays a palliative role (clinical benefit in 73% of patients) and has good tolerability. The PTX pharmacokinetic profile was unexpectedly affected by different administration time intervals; in the 0 h arm the AUC was reduced to one fourth, therefore a schedule with PTX on day one, PLD on day two may be preferred.
Collapse
Affiliation(s)
- Mario Airoldi
- Medical Oncology Department, San Giovanni Antica Sede Hospital, Turin, Italy.
| | | | | | | | | | | |
Collapse
|
50
|
Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1:297-315. [PMID: 17717971 PMCID: PMC2426795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Among several promising new drug-delivery systems, liposomes represent an advanced technology to deliver active molecules to the site of action, and at present several formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles ("first-generation liposomes") to "second-generation liposomes", in which long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle. Liposomes with modified surfaces have also been developed using several molecules, such as glycolipids or sialic acid. A significant step in the development of long-circulating liposomes came with inclusion of the synthetic polymer poly-(ethylene glycol) (PEG) in liposome composition. The presence of PEG on the surface of the liposomal carrier has been shown to extend blood-circulation time while reducing mononuclear phagocyte system uptake (stealth liposomes). This technology has resulted in a large number of liposome formulations encapsulating active molecules, with high target efficiency and activity. Further, by synthetic modification of the terminal PEG molecule, stealth liposomes can be actively targeted with monoclonal antibodies or ligands. This review focuses on stealth technology and summarizes pre-clinical and clinical data relating to the principal liposome formulations; it also discusses emerging trends of this promising technology.
Collapse
|